There is on-going development of generic EU CTD Dossier of Zolmitriptan, tablets and mouth dissolving tablets, 2.5/5 mg.

DCP slot confirmed.

Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.

Zolmitriptan is a selective serotonin receptor agonist of the 1B and 1D subtypes. It is a triptan, used in the acute treatment of migraine attacks with or without aura and cluster headaches.

Zolmitriptan is used for the acute treatment of migraines with or without aura in adults. Zolmitriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine.

Zolmitriptan is available as a swallowable tablet, an oral disintegrating tablet, and a nasal spray, in doses of 2.5 and 5 mg. People who get migraines from aspartame should not use the disintegrating tablet (Zomig ZMT), which contains aspartame.

More details at: http://www.rxlist.com/zomig-drug.htm.

• Migraine Drug Therapy (31/08/2009)
• Migraine (27/05/2008)
• Migraine (19/05/2008)

• Sildenafil citrate (17/09/2009)
• Azithromycin dihydrate (17/09/2009)
• Lercanidipine (17/09/2009)
• Irbesartan-hydrochlorothiazide (17/09/2009)
• Repaglinide (17/09/2009)
• Ropinirole HCl (17/09/2009)
• Olanzapine- mouth dissolving tablets (17/09/2009)
• Oxcarbazepine (17/09/2009)
• Losartan potassium-hydrochlorothiazide (17/09/2009)